TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36798001

Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment for transient congenital hypothyroidism (TCH)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment for permanent congenital hypothyroidism (PCH)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Levothyroxine dose of ≤3.95, ≤2.56, ≤2.19 and ≤2.12 μg/kg/day at 6 months, 1, 2 and 3 years of follow-up respectively
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Prognostic factors for transient congenital hypothyroidism (TCH)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Knee epiphyses on X-ray at diagnosis
Number of subjects: 111
Study: 36798044

Group type: EXPERIMENTAL
Intervention: Psychosocial factors associated with very infrequent HIV testing (VIT) among MSM
Number of subjects: 315
Study: 36798078

Group type: EXPERIMENTAL
Intervention: SC methylnaltrexone (0.15 mg/kg for study 302; 8 mg or 12 mg based on body weight for study 4000)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study: 36798345

Group type: EXPERIMENTAL
Intervention: Cognitive Multisensory Rehabilitation (CMR), 3 times a week, 45 minutes per session for 6 weeks, followed by a 1-year follow-up.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Observation period (Control Group B) for 6 weeks followed by 6 weeks of CMR.
Number of subjects: 26
Study: 36798353

Group type: EXPERIMENTAL
Intervention: IL-6 blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined IL-6 and EGFR blockade
Number of subjects: 0
Study: 36798485

Group type: EXPERIMENTAL
Intervention: Low oxytocin levels in AN/AtypAN-R
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Low oxytocin levels in AN/AtypAN-BP
Number of subjects: 53
Study: 36798676

Group type: EXPERIMENTAL
Intervention: Four-session tobacco cessation intervention with nicotine replacement therapy (NRT)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Re-engagement with Quitline treatment
Number of subjects: 614
Study: 36798825

Group type: EXPERIMENTAL
Intervention: BD4QoL platform (intervention arm, n=280)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Standard clinical practice (control arm, n=140)
Number of subjects: 420
Study: 36798983

Group type: EXPERIMENTAL
Intervention: CBT-I with < 5 hours of sleep
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sham-therapy with ≥ 5 hours of sleep
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: CBT-I with ≥ 5 hours of sleep
Number of subjects: 99
Study: 36799346

Group type: EXPERIMENTAL
Intervention: Bowel preparation with mannitol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36799349

Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program (DPP) intervention 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program (DPP) intervention 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36799536

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 0
Study: 36799731

Group type: EXPERIMENTAL
Intervention: HIV-PASS
Number of subjects: 187

Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 187
Study: 36799736

Group type: EXPERIMENTAL
Intervention: ASTHMAXcel PRO mobile app usage
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Higher eHealth literacy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: eHealth literacy
Number of subjects: 96
Study: 36799883

Group type: EXPERIMENTAL
Intervention: Micro-insulated needle RF device
Number of subjects: 24
Study: 36799958

Group type: EXPERIMENTAL
Intervention: Sertraline, dosage and duration not specified
Number of subjects: 0
Study: 36799961

Group type: EXPERIMENTAL
Intervention: Ketamine treatment, dosage and duration not specified
Number of subjects: 0
Study: 36800111

Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg starting dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ribociclib (400 mg single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 0
Study: 36800158

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgical technique of gastric bypass with combined upper total and lower left partial fundoplication
Number of subjects: 1
Study: 36800161

Group type: EXPERIMENTAL
Intervention: 10 µg exenatide administered subcutaneously (s.c.) as a single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.6 mg liraglutide administered s.c. once daily for 21 days
Number of subjects: 0
Study: 36800177

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36800224

Group type: EXPERIMENTAL
Intervention: Mind-Body Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36800246

Group type: EXPERIMENTAL
Intervention: 68 Ga-FAPI PET/CT
Number of subjects: 1

Group type: COMPARATOR
Intervention: 18 F-FDG PET/CT
Number of subjects: 1
Study: 36800262

Group type: EXPERIMENTAL
Intervention: Rhynorm (generic propafenone)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Rytmonorm (brand name propafenone)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Comparison of Rhynorm and Rytmonorm
Number of subjects: 76
Study: 36800277

Group type: EXPERIMENTAL
Intervention: Nonfunctional adrenal adenomas (NFAA)
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: CortisolDST 83-137 nmol/L
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: CortisolDST ≥138 nmol/L
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: CortisolDST 50-82 nmol/L in patients younger than 65 years
Number of subjects: 1154
Study: 36800433

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 36800443

Group type: EXPERIMENTAL
Intervention: SGN-CD228A (antibody-drug conjugate with MMAE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SGN-CD228A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SGN-CD228A with glucuronide linker
Number of subjects: 0
Study: 36800978

Group type: EXPERIMENTAL
Intervention: Supervised, distance-based exercise program (2 sessions of 60 minutes per week for 12 weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine care control group
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Supervised, distance-based exercise program
Number of subjects: 200
Study: 36800982

Group type: EXPERIMENTAL
Intervention: BEAM program (online group therapy and app-based mental health and parenting program)
Number of subjects: 46
Study: 36801007

Group type: EXPERIMENTAL
Intervention: Contact x-ray brachytherapy boost
Number of subjects: 141

Group type: COMPARATOR
Intervention: External beam radiotherapy boost
Number of subjects: 141
Study: 36801180

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 357
Study: 36801197

Group type: EXPERIMENTAL
Intervention: Arterial Embolization (AE)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Laparoscopic Ligation (LL)
Number of subjects: 18
Study: 36801265

Group type: EXPERIMENTAL
Intervention: Behavioral nudges delivered via electronic letters (9 different letters)
Number of subjects: 964870

Group type: COMPARATOR
Intervention: Usual care (no digitally delivered behavioral nudge)
Number of subjects: 964870

Group type: EXPERIMENTAL
Intervention: Behavioral nudges delivered via electronic letters
Number of subjects: 964870
Study: 36801430

Group type: EXPERIMENTAL
Intervention: Wearable activity tracker plus structured feedback intervention
Number of subjects: 55

Group type: COMPARATOR
Intervention: Wearable activity tracker alone
Number of subjects: 55
Study: 36801448

Group type: EXPERIMENTAL
Intervention: MSDC-0602K (250 mg)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: MSDC-0602K treatment in ZDF rats
Number of subjects: 195
Study: 36801458

Group type: EXPERIMENTAL
Intervention: EUS-guided gastroenterostomy (EUS-GE)
Number of subjects: 64
Study: 36801466

Group type: EXPERIMENTAL
Intervention: Sirolimus therapy
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: VEGF-D levels
Number of subjects: 282
Study: 36801605

Group type: EXPERIMENTAL
Intervention: Atezolizumab, platinum, pemetrexed, and bevacizumab (PPAB cohort)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Atezolizumab, platinum, and pemetrexed (PPA cohort)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: PPAB cohort
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: PPA cohort
Number of subjects: 149
Study: 36801809

Group type: EXPERIMENTAL
Intervention: Proton beam irradiation
Number of subjects: 14
Study: 36801903

Group type: EXPERIMENTAL
Intervention: Active high-definition (HD) tDCS
Number of subjects: 59

Group type: COMPARATOR
Intervention: Active conventional tDCS
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 59
Study: 36801916

Group type: EXPERIMENTAL
Intervention: Prebiotic fiber intervention for 10 days
Number of subjects: 20
Study: 36801946

Group type: EXPERIMENTAL
Intervention: Vaccinated patients with breakthrough infections
Number of subjects: 118

Group type: COMPARATOR
Intervention: Unvaccinated patients
Number of subjects: 118
Study: 36801984

Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1205
Study: 36802022

Group type: EXPERIMENTAL
Intervention: Palovarotene 5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Palovarotene 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Palovarotene (both doses)
Number of subjects: 10
Study: 36802031

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 387
Study: 36802213

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36802320

Group type: EXPERIMENTAL
Intervention: QL1206
Number of subjects: 717

Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 717
Study: 36802321

Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg every 2 weeks (Q2W)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly (QM)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo Q2W
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo QM
Number of subjects: 241
Study: 36802388

Group type: EXPERIMENTAL
Intervention: DBS coverage at 6, 12, and 24 months of ART
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Virological failure rate
Number of subjects: 578

Group type: COMPARATOR
Intervention: Risk of virological failure
Number of subjects: 578
Study: 36802389

Group type: EXPERIMENTAL
Intervention: Serrated lesions and polyps
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Males with proximal CRC
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Females with proximal CRC
Number of subjects: 231
Study: 36802690

Group type: EXPERIMENTAL
Intervention: ED-PLUS intervention (physiotherapy-led integrated care intervention)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 29

Group type: COMPARATOR
Intervention: Comprehensive Geriatric Assessment (CGA) in the ED
Number of subjects: 29
Study: 36802715

Group type: COMPARATOR
Intervention: 6 mg efpeglenatide
Number of subjects: 1360

Group type: COMPARATOR
Intervention: 4 mg efpeglenatide
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 1360
Study: 36802753

Group type: EXPERIMENTAL
Intervention: Cold Snare Polypectomy (CSP)
Number of subjects: 4270

Group type: COMPARATOR
Intervention: Hot Snare Polypectomy (HSP)
Number of subjects: 4270
Study: 36802755

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study: 36802845

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36802876

Group type: EXPERIMENTAL
Intervention: Andexanet alfa
Number of subjects: 479
Study: 36802928

Group type: EXPERIMENTAL
Intervention: Experience group sessions and 1:1 interviews
Number of subjects: 142
Study: 36802983

Group type: EXPERIMENTAL
Intervention: Hyperspectral Imaging (HSI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36803273

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (200,000 IU/1 ml of cholecalciferol)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo treatment (physiological saline (1 ml))
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 117
Study: 36803315

Group type: EXPERIMENTAL
Intervention: Physiotherapy with integrated, immersive, multimodal, therapeutic VR for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual primary physiotherapy care for 12 weeks
Number of subjects: 120
Study: 36803406

Group type: EXPERIMENTAL
Intervention: Virtual supervised tooth brushing program
Number of subjects: 1192

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1192
Study: 36803412

Group type: EXPERIMENTAL
Intervention: Subthreshold spinal cord stimulation (paresthesia-free SCS)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 114
Study: 36803444

Group type: EXPERIMENTAL
Intervention: Lower standardized involuntary care ratios
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized involuntary care ratios in 2014-2017
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized involuntary care ratios in 2015
Number of subjects: 0
Study: 36803465

Group type: EXPERIMENTAL
Intervention: Salovum (egg yolk powder enriched for antisecretory factor) during concomitant radiochemotherapy
Number of subjects: 8
Study: 36803508

Group type: COMPARATOR
Intervention: Prebiotic formula (fructo- and galactooligosaccharides)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synbiotic formula (prebiotic formula with Lactobacillus paracasei ssp. paracasei F19)
Number of subjects: 0
Study: 36803632

Group type: EXPERIMENTAL
Intervention: ZF2001 (25 μg, three doses, intramuscularly, 30 days apart)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: ZF2001
Number of subjects: 475
Study: 36803640

Group type: EXPERIMENTAL
Intervention: Next generation whole genome sequencing on the Illumina platform
Number of subjects: 537
Study: 36803645

Group type: EXPERIMENTAL
Intervention: Pyrotinib monotherapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Pyrotinib plus capecitabine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Concomitant mutations from multiple pathways in HER2-related signaling network
Number of subjects: 66
Study: 36803647

Group type: EXPERIMENTAL
Intervention: Azithromycin-based two-drug therapy
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Azithromycin-based three-drug therapy
Number of subjects: 228
Study: 36803643

Group type: EXPERIMENTAL
Intervention: Gut microbiome composition at baseline
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Fecal samples and extensive host metadata
Number of subjects: 111
Study: 36803654

Group type: EXPERIMENTAL
Intervention: XYY individuals
Number of subjects: 64

Group type: COMPARATOR
Intervention: XY controls
Number of subjects: 64
Study: 36803673

Group type: EXPERIMENTAL
Intervention: Evolutionary Systems Therapy for Schizotypy (experimental treatment)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cognitive therapy and psychopharmacological treatment (control)
Number of subjects: 24
Study: 36803737

Group type: EXPERIMENTAL
Intervention: Oral carbohydrate solution (OCS) administered before surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fasting from midnight till surgery (Control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral carbohydrate solution (OCS)
Number of subjects: 50
Study: 36803773

Group type: EXPERIMENTAL
Intervention: Shared medical appointments (SMAs)
Number of subjects: 0
Study: 36803835

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (M-Body), eight weekly, 90-min group sessions
Number of subjects: 274

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 274
Study: 36803837

Group type: EXPERIMENTAL
Intervention: 3 weeks of post-surgical systemic antibiotic therapy for implant-free infections
Number of subjects: 280

Group type: COMPARATOR
Intervention: 6 weeks of post-surgical systemic antibiotic therapy for implant-free infections
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: 6 weeks of post-surgical systemic antibiotic therapy for residual implant-related infections
Number of subjects: 280

Group type: COMPARATOR
Intervention: 12 weeks of post-surgical systemic antibiotic therapy for residual implant-related infections
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Post-surgical systemic antibiotic therapy
Number of subjects: 280
Study: 36803840

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg IV every 3 weeks for ≤96 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg IV every 3 weeks for ≤96 weeks + BCG (50 mg) induction and maintenance
Number of subjects: 24

Group type: COMPARATOR
Intervention: BCG (50 mg) induction and maintenance
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 24
Study: 36803873

Group type: EXPERIMENTAL
Intervention: GOS-3 group (pre-admission GOS score of 3)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Age above 59 years
Number of subjects: 499

Group type: COMPARATOR
Intervention: Preexisting ultimately fatal comorbidity
Number of subjects: 499

Group type: COMPARATOR
Intervention: Refractory CSE
Number of subjects: 499

Group type: COMPARATOR
Intervention: Cerebral insult as the cause of CSE
Number of subjects: 499

Group type: COMPARATOR
Intervention: Logistic Organ Dysfunction score ≥ 3 at ICU admission
Number of subjects: 499

Group type: COMPARATOR
Intervention: Preadmission GOS score of 3
Number of subjects: 499
Study: 36803892

Group type: EXPERIMENTAL
Intervention: Epidural corticosteroid injection
Number of subjects: 78
Study: 36803992

Group type: EXPERIMENTAL
Intervention: High-dose oral ivermectin (600 µg/kg daily for 7 days)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies casirivimab and imdevimab (600 mg/600 mg)
Number of subjects: 205

Group type: COMPARATOR
Intervention: No study drug
Number of subjects: 205
Study: 36804035

Group type: EXPERIMENTAL
Intervention: Obex®
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study: 36804046

Group type: EXPERIMENTAL
Intervention: iCanQuit alone
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: iCanQuit+Motiv8 combined
Number of subjects: 444

Group type: COMPARATOR
Intervention: Florida Quitline
Number of subjects: 444
Study: 36804053

Group type: EXPERIMENTAL
Intervention: Ipilimumab (anti-CTLA-4) added to atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 36804093

Group type: EXPERIMENTAL
Intervention: Zavegepant 10 mg nasal spray
Number of subjects: 1405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1405
Study: 36804094

Group type: EXPERIMENTAL
Intervention: Baliforsen 100 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Baliforsen 200 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Baliforsen 300 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Baliforsen 400 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Baliforsen 600 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Baliforsen
Number of subjects: 49
Study: 36804149

Group type: EXPERIMENTAL
Intervention: Mild local hyperthermia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 0
Study: 36804173

Group type: EXPERIMENTAL
Intervention: Wrist-worn photoplethysmography (PPG) sensor for heart rate (HR) and respiratory rate (RR) measurements
Number of subjects: 62
Study: 36804286

Group type: EXPERIMENTAL
Intervention: aboBoNT-A 500U
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: aboBoNT-A 300U
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 36804322

Group type: EXPERIMENTAL
Intervention: Moderate-dose group (4 mg total carotenoids/d, 177 mL orange-carrot juice/d)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: High-dose group (8 mg total carotenoids/d, 355 mL orange-carrot juice/d)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (negligible carotenoids, 177 mL apple juice/d)
Number of subjects: 162
Study: 36804420

Group type: EXPERIMENTAL
Intervention: FMNCP intervention (16 coupon sheets valued at $21 per sheet over 10-15 wk)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: FMNCP intervention
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 285
Study: 36804450

Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) intervention including motivational interviewing and behavioral activation for 12 months
Number of subjects: 800

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 800
Study: 36804834

Group type: EXPERIMENTAL
Intervention: BPaL regimen (high-dose linezolid, bedaquiline, and pretomanid)
Number of subjects: 93
Study: 36805024

Group type: EXPERIMENTAL
Intervention: Brief four-module ICBT program (n = 22)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 43
Study: 36805083

Group type: EXPERIMENTAL
Intervention: Gene therapy with AAV8-LSPhGAA (1.6 × 10^13 vg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 0
Study: 36805095

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Higher calorie intake
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Higher protein intake
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Substantial protein (≥0.4 g/kg/d) or calorie (≥5 kcal/kg/d) gap between targeted or actual intake
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: History of diabetes mellitus, male sex, higher BMI, in-hospital infections, necessity for invasive mechanical ventilation
Number of subjects: 107